Global EditionASIA 中文双语Français
Business
Home / Business / Companies

F-star, Takeda collaborate to develop new generation immunotherapies

By Liu Zhihua | chinadaily.com.cn | Updated: 2023-07-06 14:50
Share
Share - WeChat

China's pharmaceutical conglomerate Sino Biopharmaceutical Limited, or Sino Biopharm, announced on Wednesday that its wholly-owned subsidiary F-star Therapeutics Limited in Cambridge, UK has reached a strategic cooperation and entered into a licensing agreement with Takeda, a well-known Japanese pharmaceutical company.

The collaboration will leverage F-star's proprietary medicine development platforms to research and develop next-generation multi-specific immunotherapies for patients with cancer.

F-star will receive an undisclosed upfront payment and research funding during the collaboration and is entitled to potential development and commercialization milestone payments of up to $1 billion, plus potential annual net sales of any commercial products licensed amount of patent royalties.

The cooperation and licensing agreement, the third licensing agreement signed between F-star and Takeda within one year, further demonstrates the great potential of F-star's multi-antibody platform and is another achievement of China's biopharmaceutical internationalization innovation model, Sino Biopharm said.

In March of this year, Sino Biopharmaceutical successfully acquired F-star, which is an internationally leading biotechnology company in the research and development of dual antibody platforms. 

liuzhihua@chinadaily.com.cn

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE